A Long-Term Safety Study of Asoprisnil in the Treatment of Uterine Fibroids.

This study has been completed.
Information provided by:
ClinicalTrials.gov Identifier:
First received: September 7, 2005
Last updated: March 3, 2009
Last verified: May 2008
This study was designed to determine the long-term safety of asoprisnil 10 mg in women with one or more uterine fibroids after an initial 12 weeks in study M99-144.

Condition Intervention Phase
Drug: Asoprisnil
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 2, Long-Term, Open-Label, Safety Extension Study of Asoprisnil (J867) in Patients With Uterine Leiomyomata

Further study details as provided by Abbott:

Primary Outcome Measures:
  • Percent change from baseline in uterine volume and volume of the largest fibroid from pre-treatment in study M99-144 [ Time Frame: Treatment months 3 and 6 and Post-treatment months 3 and 6 ] [ Designated as safety issue: No ]
  • Percentage of subjects that achieved amenorrhea. [ Time Frame: Treatment months 1-6 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Improvement in hematologic parameters. [ Time Frame: Treatment months 2,4,and 6 ] [ Designated as safety issue: Yes ]
  • Improvement in Uterine fibroid symptoms(menorrhagia, metrorrhagia, pelvic pressure, bloating, urinary disorders, pelvic pain, dysmenorrhea, dyspareunia) using a 4 point scale [ Time Frame: Treatment Months 1-6 ] [ Designated as safety issue: No ]
  • Change from baseline in uterine size in gestational weeks. [ Time Frame: Months 3 and 6 ] [ Designated as safety issue: No ]
  • Duration of amenorrhea. [ Time Frame: Start of previous study to first post-treatment menses. ] [ Designated as safety issue: No ]
  • Response to global efficacy question regarding improvement of fibroid symptoms. [ Time Frame: Month 6 ] [ Designated as safety issue: No ]
  • Mean change from baseline for endocrine determinations. [ Time Frame: Months 2,4 and 6 ] [ Designated as safety issue: Yes ]

Enrollment: 38
Study Start Date: April 2001
Study Completion Date: December 2001
Primary Completion Date: December 2001 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Asoprisnil
10mg Tablet, oral Daily for 6 months

Detailed Description:
No medical therapy is currently available for the long-term treatment of uterine fibroids. The objective of this study is to determine the long-term safety of asoprisnil 10 mg daily for 6 months, after an initial 12 weeks in study M99-144, in women with one or more uterine fibroids, confirmed by ultrasound in study M99-144. The safety endpoints for this study will be based on ultrasound and endometrial biopsy results, adverse events, and any changes from baseline laboratory values and vital signs.

Ages Eligible for Study:   18 Years to 48 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Completed dosing and Day 84 procedures at sites in study M99-144
  • No interruption of dosing
  • Otherwise continued good health

Exclusion Criteria:

  • Any abnormal lab result the study-doctor considers significant
  • History of severe reaction to or current use of hormone therapy
  • History of alcohol or drug abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00156182

Sponsors and Collaborators
Study Chair: Medical Director Abbott
  More Information

Responsible Party: Cynthia Mattia-Goldberg, Abbott
ClinicalTrials.gov Identifier: NCT00156182     History of Changes
Other Study ID Numbers: M01-275 
Study First Received: September 7, 2005
Last Updated: March 3, 2009
Health Authority: United States: Food and Drug Administration
Canada: Health Canada

Keywords provided by Abbott:
Fibroid Uterus
Uterine Fibroids

Additional relevant MeSH terms:
Connective Tissue Diseases
Neoplasms by Histologic Type
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms, Muscle Tissue

ClinicalTrials.gov processed this record on May 25, 2016